who receive tumor necrosis factor (TNF) inhibitors after being diagnosed with early-stage colorectal, lung, or prostate cancer have similar survival outcomes as those who receive conventional ...

Using vedolizumab first, before tumor necrosis facor-α inhibitors, improved quality-adjusted life-years in both ulcerative ...

I think combination therapy is coming; it’s just a question of which combinations,’ says Arthur Kavanaugh, MD.

Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It's used to treat several types of ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and ...

5 The global market value for TNF inhibitor drugs was estimated to be $39.7 billion in 2024. Growing at an expected CAGR of 3.6% for the next five years, the TNF inhibitor market is expected to ...

Discover a study that assessed the risk of hospitalisation for serious infections based on different categories of systemic ...

The study compared overall deaths, and deaths due to cancer, among patients using TNF inhibitors vs. those on conventional synthetic disease-modifying anti-rheumatic drugs. The researchers ...

Common options include nonsteroidal anti-inflammatory drugs (NSAIDs), tumor necrosis factor (TNF) inhibitors, and steroids. NSAIDs such as aspirin, ibuprofen (Advil, Motrin), indomethacin ...